Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph B Muhlestein

Showing results (1-10 of 213) with videos related to

Pageof 22
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Secondary prevention of coronary artery disease with antimicrobials: current status and future directionsJoseph B Muhlestein
Current Opinion in Lipidology|November 19, 2003
Antibiotic treatment of atherosclerosisJoseph B Muhlestein
Drugs & Aging|July 21, 2004
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarctionJoseph B Muhlestein
Thrombosis and Haemostasis|January 12, 2010
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patientsJoseph B Muhlestein
Drugs in R&D|August 31, 2013
Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic anginaJoseph B Muhlestein, Sharon Grehan
Texas Heart Institute Journal|April 6, 2004
Antibiotic trials for coronary heart diseaseJeffrey L Anderson, Joseph B Muhlestein
Journal of Interventional Cardiology|March 25, 2005
Early initiation of statin therapy in acute coronary syndromes: a review of the evidenceMatthew T Rondina, Joseph B Muhlestein
Cardiology Clinics|November 19, 2003
Chronic infection and coronary artery diseaseJoseph B Muhlestein, Jeffrey L Anderson
JACC. Cardiovascular Imaging|March 11, 2017
Primary Prevention of CVD: The Role of Imaging TrialsAlan Rozanski, Joseph B Muhlestein, Daniel S Berman
The American Journal of Clinical Nutrition|July 3, 2015
Health effects of intermittent fasting: hormesis or harm? A systematic reviewBenjamin D Horne, Joseph B Muhlestein, Jeffrey L Anderson
Pageof 22

Showing results (1-10 of 213) with videos related to

Sort By:
Pageof 22
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
Secondary prevention of coronary artery disease with antimicrobials: current status and future directionsJoseph B Muhlestein
Current Opinion in Lipidology|November 19, 2003
Antibiotic treatment of atherosclerosisJoseph B Muhlestein
Drugs & Aging|July 21, 2004
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarctionJoseph B Muhlestein
Thrombosis and Haemostasis|January 12, 2010
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patientsJoseph B Muhlestein
Drugs in R&D|August 31, 2013
Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic anginaJoseph B Muhlestein, Sharon Grehan
Texas Heart Institute Journal|April 6, 2004
Antibiotic trials for coronary heart diseaseJeffrey L Anderson, Joseph B Muhlestein
Journal of Interventional Cardiology|March 25, 2005
Early initiation of statin therapy in acute coronary syndromes: a review of the evidenceMatthew T Rondina, Joseph B Muhlestein
Cardiology Clinics|November 19, 2003
Chronic infection and coronary artery diseaseJoseph B Muhlestein, Jeffrey L Anderson
JACC. Cardiovascular Imaging|March 11, 2017
Primary Prevention of CVD: The Role of Imaging TrialsAlan Rozanski, Joseph B Muhlestein, Daniel S Berman
The American Journal of Clinical Nutrition|July 3, 2015
Health effects of intermittent fasting: hormesis or harm? A systematic reviewBenjamin D Horne, Joseph B Muhlestein, Jeffrey L Anderson
Pageof 22